NCT07190209 - Efficacy, Safety, and Tolerability Study of Lunsekimig Compared With Placebo in Adult Participants With Inadequately Controlled Chronic Obstructive Pulmonary Disease (COPD) Characterized by an Eosinophilic Phenotype | Biotech Hunter

Enrollment

942

Participants

Timeline

Start Date

September 16, 2025

Primary Completion Date

November 27, 2029

Study Completion Date

January 22, 2030

Conditions

Chronic Obstructive Pulmonary Disease

Interventions

DRUG

Lunsekimig

Pharmaceutical form: solution for injection in prefilled syringe Route of administration: Subcutaneous injection

DRUG

Placebo

Pharmaceutical form: solution for injection Route of administration: Subcutaneous injection

Trial Locations (11)

33014

RECRUITING

Deluxe Health Center- Site Number : 8400010, Miami Lakes

33024

RECRUITING

Broward Research Center- Site Number : 8400053, Pembroke Pines

33126

RECRUITING

MCR Research- Site Number : 8400004, Miami

33144

RECRUITING

Nuren Medical and Research Center - Site Number : 8400030, Miami

33435

RECRUITING

Helix Biomedics, LLC- Site Number : 8400065, Boynton Beach

33607

RECRUITING

Clinical Research Trials of Florida, Inc- Site Number : 8400011, Tampa

73081

RECRUITING

Epic Medical Research- Site Number : 8400097, Chickasha

75115

RECRUITING

Epic Medical Research- Site Number : 8400095, DeSoto

78229

RECRUITING

DCT - Corporate, LLC dba Discovery Clinical Trials- Site Number : 8400031, San Antonio

92663

RECRUITING

Newport Native MD- Site Number : 8400003, Newport Beach

N1H 6J2

RECRUITING

Investigational Site Number : 1240004, Guelph